UCP2 and cervical cancer: We then aimed to validate the RNA expression data through immunohistochemistry using antibodies against UCP2 and STAT1 in 20 cervical precursor lesions (5 cervicitis, 5 LSIL, 5 HSIL) and 5 cervical cancer samples from 20 patients in a previously described cohort (cohort 2) (19).